Seres Therapeutics (MCRB) Revenue (2016 - 2026)

Seres Therapeutics has disclosed Revenue across 10 years of filings, most recently posting $736000.0 for Q2 2026.

• In Q2 2026, Revenue changed N/A year-over-year to $736000.0; the TTM figure through Jun 2026 stood at $1.9 million (changed N/A YoY), while the FY2025 annual figure was $789000.0, changed N/A from the prior year.
• Revenue came in at $736000.0 for Q2 2026 at Seres Therapeutics, up from $358000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $126.5 million in Q2 2023 to a low of -$126.3 million in Q4 2023.
• Average Revenue over 4 years is $837916.7, with a median of $629000.0 recorded in 2023.
• The largest YoY upside for Revenue was 10300.74% in 2023 against a maximum downside of 13049.85% in 2023.
• Over 4 years, Revenue stood at $975000.0 in 2022, then tumbled by 13049.85% to -$126.3 million in 2023, then soared by 100.35% to $438000.0 in 2025, then jumped by 68.04% to $736000.0 in 2026.
• Per Business Quant data, the three most recent Revenue figures were $736000.0 in Q2 2026, $358000.0 in Q1 2026, and $438000.0 in Q4 2025.